STAT3 and hepatocellular carcinoma: Astragaloside IV blocked the polarization of TAMs towards M2-like phenotypes via suppressing the activation of the TLR4/NF-κB/STAT3 signaling pathway, thus recovering the innate immunity to inhibit the proliferation of HCC cells [124].